Senior Bioinformatics Scientist, Cancer NGS Lab
KEW Group is currently seeking a full time Senior Bioinformatics Scientist to enhance analysis of DNA sequencing data for our growing CLIA/CAP‐certified clinical lab in Cambridge, MA. The scope of this role will include developing, automating and implementing DNA sequencing analysis in collaboration with our clinical analytics team. Primary Responsibilities: - Develop, enhance and automate analysis of high quality DNA sequencing data in CAP/CLIA‐certified lab environment. - Work with medical lab operators in our CAP/CLIA‐certified to assess and document analytics accuracy, precision, sensitivity, specificity and robustness. - Work with clinical analytics team to annotate variants and generate content for use in clinical reports. - Provide robust, reliable variant calls and ensure high quality data generation while complying with security and privacy requirements. Qualifications: - MS or PhD in bioinformatics or computational biology and 2+ years of experience in industry setting. - Working knowledge and deep understanding of algorithms, data structures, and scientific programming. - Working experience with next generation sequencing data using common NGS tools (e.g. BWA, GATK, Samtools, Picard, TopHat, and Cufflinks) as well as development of novel tools. - Experience in a Unix / Linux environment. - Deep knowledge of at least one “compiled” programming language, such as Go, C/C++, or Java. - Proficiency in scripting languages such as Perl or Python. - Experience in high performance computing, clusters and cloud computing. - Must be able to work in the US.
Interested candidates should submit their resume in Word or PDF format to firstname.lastname@example.org with “BIOINFORMATICS” in the subject line.
The KEW Group is a personalized medicine company focused on providing oncologists access to the latest genomic insights to guide them in designing optimal, individualized treatment approaches for patients. KEW’s mission is to revolutionize cancer care by determining which treatments will work best for which patients and offering clinicians specific and practical, action‐oriented solutions. KEW does this by coupling comprehensive patient‐specific genomic data generated by their proprietary genomics‐based CancerPlex® test together with expert‐curated, evidence‐based information about approved and emerging therapies. These results, including clinical trial and specific therapeutic recommendations, are then utilized by oncologists to guide treatment decisions and advance optimal patient care. The KEW Group is an equal opportunity employer.